

1 **Title: Obesity associated with attenuated tissue immune cell responses in COVID-19**

2

3 **Authors:**

4 Shuang A. Guo^{1,2,3,4^}, Georgina S. Bowyer^{1,3,4^}, John R. Ferdinand^{1,3,4^}, Mailis Maes^{3,4^}, Zewen K.
5 Tuong^{1,2,3,4^}, Eleanor Gilman^{1,3,4}, Mingfeng Liao⁵, Rik G. H. Lindeboom², Masahiro Yoshida⁶,
6 Kaylee Worlock⁶, Huda Gopee⁷, Emily Stephenson⁷, Paul A. Lyons^{3,4,8}, Kenneth G.C. Smith^{3,4,8},
7 Muzlifah Haniffa^{2,7}, Kerstin B. Meyer², Marko Z. Nikolic⁶, Zheng Zhang⁵, Richard G. Wunderink⁹,
8 Alexander V. Misharin⁹, Gordon Dougan^{3,4,8}, Vilas Navapurkar¹⁰, Sarah A. Teichmann^{2*}, Andrew
9 Conway-Morris^{10,11*}, Menna R. Clatworthy^{1,2,3,4,8*}.

10

11

12 **Affiliations:**

13 ¹Molecular Immunity Unit, Department of Medicine, University of Cambridge, Cambridge, UK.

14 ²Cellular Genetics, Wellcome Sanger Institute, Hinxton, UK.

15 ³Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah
16 Biomedical Centre, University of Cambridge, Cambridge, CB2 0AW, UK.

17 ⁴Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge,
18 CB2 0QQ, UK

19 ⁵Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen
20 Third People's Hospital, Shenzhen, China.

21 ⁶UCL Respiratory, Division of Medicine, University College London, London, UK

22 ⁷Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK

23 ⁸NIHR Cambridge Biomedical Research Centre, Cambridge, UK.

24 ⁹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of
25 Medicine, Northwestern University, Chicago, IL, USA.

26 ¹⁰John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge University Hospitals
27 NHS Foundation Trust, Cambridge, UK

28 ¹¹Division of Anaesthesia, University of Cambridge Department of Medicine, Cambridge, UK.

29 [^]Equal contribution

30 ^{*}Corresponding authors

31

32 **Abstract**

33 Obesity is common and associated with more severe COVID-19, proposed to be in part related to
34 an adipokine-driven pro-inflammatory state. Here we analysed single cell transcriptomes from
35 bronchiolar lavage in three adult cohorts, comparing obese (Ob, body mass index (BMI) $>30\text{m}^2$)
36 and non-obese (N-Ob, BMI $<30\text{m}^2$). Surprisingly, we found that Ob subjects had attenuated lung
37 immune/inflammatory responses in SARS-CoV-2 infection, with decreased expression of
38 interferon (IFN) α , IFN γ and tumour necrosis factor (TNF) alpha response gene signatures in
39 almost all lung epithelial and immune cell subsets, and lower expression of *IFNG* and *TNF* in
40 specific lung immune cells. Analysis of peripheral blood immune cells in an independent adult
41 cohort showed a similar, but less marked, reduction in type I IFN and IFN γ response genes, as
42 well as decreased serum IFN α , in Ob patients with SARS-CoV-2. Nasal immune cells from Ob
43 children with COVID-19 also showed reduced enrichment of IFN α and IFN γ response genes.
44 Altogether, these findings show blunted tissue immune responses in Ob COVID-19 patients, with
45 clinical implications.

46

47 **Main**

48 SARS-CoV-2 is a novel coronavirus responsible for the current global pandemic, with more than
49 275 million cases and 5.3 million deaths confirmed worldwide (World Health Organisation, Dec
50 24th 2021). The clinical course of SARS-CoV-2 is variable, ranging from asymptomatic disease to
51 acute respiratory distress syndrome requiring ventilatory support¹. Those at risk of a more severe
52 clinical course following infection include the elderly, immunosuppressed, and those with co-
53 morbidities including obesity¹⁻⁴. Despite the expedited delivery of clinically validated SARS-CoV-
54 2 vaccines, some 'vulnerable' groups mount poor vaccine responses, and emerging viral variants
55 are poorly neutralised by vaccine-induced antibodies⁵. Thus, there is an on-going need to better
56 understand viral immune responses in those at highest risk of severe disease, such as obese
57 individuals.

58

59 Obesity, defined as a body mass index (BMI) of $>30\text{m}^2$, is common and affects more than 40% of
60 US adults⁶. Whilst an increased BMI generates mechanical factors that may compromise
61 ventilation⁷, obesity is also associated with an inflammatory state characterised by elevated
62 circulating cytokines such as tumour necrosis factor (TNF) and interleukin (IL) 6⁸, chemokines,
63 including the neutrophil recruiting chemokine CXCL8⁹, and the monocyte chemoattractant CCL2
64 (MCP1) that mediates the accumulation of inflammatory adipose tissue macrophages¹⁰.
65 Lymphocyte abnormalities have also been noted in obesity, and an increased frequency of
66 circulating interferon (IFN)- γ secreting CD4 T cells noted, the latter likely related to the known
67 effects of leptin in promoting Th1 polarisation¹¹. Indeed, the appetite-regulating hormone leptin,
68 produced by adipocytes and increased in obesity, has several direct immune stimulatory effects,

69 promoting NK cell cytotoxicity, antigen presentation by dendritic cells (DC) and monocyte and B
70 cell secretion of TNF and IL6 by engagement of the leptin receptor (LEPR) which is expressed on
71 many immune cells, and principally acts by triggering JAK2/STAT3 signalling¹². Leptin levels
72 increase in lean animals challenged with pro-inflammatory cytokines, infectious agents or
73 pathogen-derived molecules¹³, and in COVID-19, elevated serum leptin levels have been
74 described in ventilated SARS-CoV-2 patients compared with controls¹⁴, with a positive correlation
75 with BMI¹⁵.

76
77 There has been an intense focus on delineating the nature of the immune response in SARS-
78 CoV-2 infection; Type I IFN responses play a critical role in protective immunity, with genetic-
79 deficiency or neutralising autoantibodies affecting this axis mediating increased susceptibility to
80 severe infection¹⁶. Transcriptomic studies have identified both absent/low and increased IFN
81 response genes in patients with severe or lethal disease, and longitudinal studies revealed a
82 diminished and/or delayed induction of type I IFNs in COVID-19 patients compared with patients
83 with influenza, with an exuberant early TNF/IL6 response¹⁶. To date, the effect of obesity on
84 immune responses to SARS-CoV-2, particularly tissue responses, has not been considered,
85 although it has been proposed that the elevated leptin associated with obesity might promote an
86 excessive inflammatory response, contributing to the worse outcomes observed in obese patients
87 with COVID-19, with calls for anti-inflammatory therapeutic strategies to be employed in this
88 patient group¹⁷.

89
90 Here we profiled paired blood and bronchoalveolar lavage (BAL) samples from 4 patients with
91 severe COVID-19 requiring mechanical ventilation and intensive care treatment, and 4 control
92 ventilated non-COVID-19 patients using flow cytometry and scRNAseq. To address the issue of
93 whether patients with a high BMI have abnormal tissue immune responses to SARS-CoV-2, we
94 integrated our scRNAseq data (UCAM) with two previous COVID-19 BAL scRNAseq datasets
95 from Shenzhen 3rd Hospital, China (SZH) and Northwestern University, Chicago, USA (NU)^{18,19}
96 and obtained the BMI metadata associated with these samples, enabling a comparison of BAL
97 immune cells in 13 obese (Ob) patients (BMI>30) and 20 non-obese (N-Ob) (BMI<30) COVID-19
98 patients and ventilated non-COVID controls (**Fig. 1a, S1a**). Overall, Ob subjects were more
99 prevalent in the NU cohort compared to the other two cohorts and underwent BAL sampling at
100 earlier time-points following admission to the intensive care unit (**Fig. S1a**).

101
102 Following QC, dataset integration and batch correction, data was available on 189,312 cells.
103 Clusters were broadly annotated using canonical marker expression and comparison to previously
104 published BAL single cell datasets, to identify alveolar type 1 and 2 pneumocytes (AT1/2), ciliated
105 cells, B and plasma cells, classical and plasmacytoid dendritic cells (c/pDCs), a broad T cell/innate
106 lymphocyte cluster and alveolar macrophages, including monocyte-derived and tissue-resident

107 clusters, with reasonable representation of cells from Ob and N-Ob patients in all clusters (**Fig.**
108 **1b, S1b-c**).

109

110 Analysis of the non-immune cells in isolation enabled the identification of several ciliated epithelial
111 cell subsets, as well as basal cells, club cells, squamous cells and alveolar type 1 and AT1/2 (**Fig.**
112 **1c, S2a**). Organ structural cells may contribute to tissue immune responses, and indeed, several
113 immune-related transcripts were highly expressed in some of these subsets; SARS-CoV-2-
114 infected AT1/2 cells expressed neutrophil recruiting chemokine transcripts (*CXCL1*, *CXCL2* and
115 *CXCL8*), but this was attenuated in Ob compared with N-Ob subjects (**Fig. S2b**). Consistent with
116 this, flow cytometric analysis of the UCAM cohort BAL confirmed a reduction in neutrophils in Ob
117 BAL compared with N-Ob BAL (**Fig. S2c**). *IL1RN* (encoding IL1RA, a protein that binds to IL1R
118 inhibiting the pro-inflammatory effects of IL1 β , including arterial inflammation²⁰) was highly
119 expressed in squamous epithelial cells in N-Ob, whilst barely detectably in Ob subjects (**Fig. S2b**).
120 Conversely, GDF15 the pro-cachectic cytokine²¹ was more highly expressed in Ob subjects across
121 a range of airway cells (**Fig. S2b**). Surprisingly, given the association of obesity with inflammation,
122 gene-set enrichment analysis (GSEA) demonstrated a marked negative enrichment of *interferon-*
123 *alpha* and/or *interferon-gamma response genes* in all non-immune cell clusters in Ob compared
124 with N-Ob COVID-19+ BAL, with more variable differences in these genesets in COVID-19
125 negative patients (**Fig. 1d**).

126 Considering alveolar macrophages in isolation, four subsets of monocyte-derived macrophages
127 (MoAM), and two subsets of tissue resident (TRAM1/2) macrophages were evident, as noted
128 previously^{18,19} (**Fig. 1e, S2d**). In Ob subjects with SARS-CoV-2 infection, all alveolar macrophage
129 subsets showed reduced enrichment of *interferon-alpha* and/or *interferon-gamma response*
130 *genes*, *Tnfa via NFkB*, *Inflammatory response*, and *complement pathway genes*, with reduced
131 *JAK-STAT3 signalling pathway genes* also evident in MoAM1,2 and 4 compared with N-Ob
132 COVID-19 (**Fig. 1f, S2e**), with a similar pattern observed in cDCs and pDCs in BAL (**Fig.S2f**).
133 Indeed, a curated chemokine/cytokine gene module score was significantly higher in N-Ob
134 alveolar macrophages, particularly in monocyte-derived AM subsets (**Fig. 1g**). Given the
135 differences in timing of BAL sampling between groups, we plotted individual patient gene pathway
136 enrichment scores against time (**Fig. S2g**). This confirmed that *interferon-alpha* and/or *interferon-*
137 *gamma response genes* were reduced in Ob compared with N-Ob subjects, across timepoints,
138 and in all AM subsets except TRAM2, which showed only an early attenuation of responses in Ob
139 (**Fig. S2g**). Genes attenuated in Ob alveolar macrophages and cDCs included *CXCL10*, a
140 classical IFN γ response gene previously proposed to form a pro-inflammatory circuit with T cells¹⁹,
141 and several monocyte and lymphocyte-recruiting chemokines (**Fig. S2h-i**). A notable exception to
142 the muted cytokine and chemokine expression in Ob macrophages, cDCs and pDCs was *TGFB1*,
143 a tissue repair factor, which in excess can contribute to fibrosis, which was broadly more highly
144 expressed in Ob cells in COVID-19 (**Fig. S2h-i**). To validate these findings and confirm their

145 relevance across lifespan, we examined the single cell transcriptomes of tissue immune cells
146 isolated from nasal brushings in children with SARS-CoV-2²². We similarly found reduced
147 enrichment of *interferon-alpha* and/or *interferon-gamma response* genes in myeloid cells in Ob
148 children compared with N-Ob (**Fig. 1h**).

149
150 We next assessed T cells and innate lymphocytes in adult BAL, annotating naïve and effector
151 memory CD4 and CD8 subsets, Tregs, MAIT cells, NKT and two subsets of NK cells, CD56^{high}
152 and CD56^{low} (**Fig. 2a, S3a**). GSEA again demonstrated reduced enrichment of *interferon-alpha*
153 and/or *interferon-gamma response* genes, and *Tnfa signalling via NFkB*, pathway genes across
154 every subset present in Ob BAL (**Fig. 2b, S3b-c**). In Ob children with SARS-CoV-2, nasal T cells
155 and innate lymphocytes cells also showed reduced enrichment of *interferon-alpha* and/or
156 *interferon-gamma response* genes compared with N-Ob (**Fig. 2c, S3d**).

157 In adult BAL, predictive cell-cell interaction analysis based on receptor-ligand expression
158 suggested reduced alveolar macrophage production of chemokines (*CCL7, CCL8*) predicted to
159 attract CD8 T and NK cell subsets in Ob subjects (**Fig. 2d**), both important for anti-viral immunity.
160 Few predicted interactions were increased in Ob patients, notably IL10-IL10R (MoMAC3/4 and
161 NKCD56^{hi}) with the potential to suppress NK cell cytotoxicity²³, and TNFSF14-TNFRSF14
162 (MoMAC1/3 and naïve CD8 T cells) (**Fig. 2d**), encoding LIGHT-HVEM, an axis important for
163 stimulating lymphocytes, but high serum LIGHT levels have been associated with fatal COVID-
164 19²⁴.

165 B cell and plasma cells clusters in adult BAL included naïve B cells, memory B cells, exhausted B
166 cells and plasma cells. (**Fig. 2e, S4a-b**). In COVID-19, there was again reduced enrichment of
167 *interferon-alpha* and/or *interferon-gamma response* and *Tnfa signalling via NFkB* pathway genes
168 in all BAL B cell subsets in Ob subjects, with more variable effects in the paediatric samples (**Fig.**
169 **2f, S4c-d**).

170
171 To determine if blunted immune responses were evident in Ob subjects beyond tissue immune
172 cells, we obtained BMI data (where available) on an additional cohort of adult COVID-19 patients
173 recently included in a multiomic analysis of PBMCs²⁵. In this cohort, patient's blood was sampled
174 between day 0 and 20 post-symptom onset, with a similar temporal distribution of sampling in Ob
175 and Non-Ob (**Fig. S5a**). As observed in adult BAL, there was reduced enrichment of *interferon-*
176 *alpha* and/or *interferon-gamma response genes* in peripheral blood T cells, innate lymphocytes
177 and B cells in Ob COVID-19 patients compared with N-Ob (**Fig. S5b-c**). Interestingly, *Tnfa*
178 *signalling via NFkB* pathway genes showed the opposite enrichment pattern to that observed in
179 BAL, with an increase in Ob COVID-19 patients (**Fig. S5b-c**).

180
181 We reasoned that the reduced tissue cell responses to IFN α , IFN γ and TNF α might be due to a
182 decreased production of these cytokines, or a reduced ability to respond to them due to decreased

183 receptor expression. To distinguish between these possibilities, we first assessed cytokine
184 transcripts in BAL cells; *IFNA1/2* and *IFNB* transcripts were undetectable, except in <0.5% of
185 MoAM3 in N-Ob COVID-19+ subjects (**Fig. 2g, S6**). There was little expression of type I IFN
186 transcripts in peripheral blood immune cells (**Fig. S7**), but serum cytokine measurement showed
187 undetectable IFN α levels in Ob but elevated levels in N-Ob subjects (**Fig. 2h**), with no significant
188 differences in TNF (which was undetectable) and IFN γ (data not shown). *IFNAR1/2* expression
189 was not decreased in Ob versus N-Ob COVID-19 BAL cells, with an increase in *IFNAR1* in some
190 alveolar macrophage subsets in Ob COVID-19 (**Fig. 2g, S6**). Altogether, this is consistent with a
191 failure of type I IFN production rather than a reduced ability to respond to type I IFNs in Ob subjects
192 in COVID-19. In SARS-CoV-2 infected patients, *IFNG* transcripts were detectable in proliferating
193 lymphocytes, CD4 central memory T cells, naïve CD8 T cells and NKT cells in BAL, again mainly
194 at a higher level in N-Ob compared with Ob patients (**Fig. S6**). In BAL, *TNF* transcripts were
195 highest in N-Ob COVID-19+ MoAM3, TRAM2, and cDC (**Fig. 2g, S6**), but in blood, the opposite
196 was observed, with higher *TNF* and lower *TNFRSF1A/B* expression in some subsets of Ob
197 circulating monocytes (**Fig. S8**).

198
199 Obese patients are known to have basal immune activation and inflammation, in part due to the
200 immunostimulatory effects of elevated leptin. It has been proposed that this contributes to the
201 increased susceptibility to severe SARS-CoV-2 infection and the worse outcomes observed in
202 obese subjects, generating a heightened pro-inflammatory cytokine response. In fact, our analysis
203 of Ob adult BAL and Ob paediatric nasal immune cells in COVID-19 suggests that these patients
204 exhibit a broadly immunosuppressed state in tissues compared with non-obese subjects, with
205 reduced type I IFN and IFN gamma signatures across almost all immune cell subsets, as well as
206 decreased expression of monocyte and neutrophil recruiting chemokines. Of note, our findings
207 bare similarity to studies of obese mice challenged with influenza, which not only had increased
208 mortality, but decreased *Ifna*, *Ifnb* and *Ifng* transcripts in lung tissue, as well as lower levels of
209 some chemokines (*Ccl2* and *Ccl5*), compared with lean controls, despite a higher viral load^{13,26}.
210 In addition, these obese animals also had impaired antigen presentation by DC, decreased IFN- γ
211 production by memory T cells, and reduced NK cell cytotoxicity in this model²⁷. Interestingly, serum
212 leptin concentrations increased in lean mice during influenza infection, in contrast to obese mice,
213 where leptin decreased, such that during infection levels were similar to lean mice¹³ but leptin
214 resistance in the latter contributing to attenuated immune cell responses²⁸. Consistent with this, in
215 COVID-19 BAL, we observed reduced *JAK-STAT3 signalling* pathway genes in a number of lung
216 immune cell subsets in Ob subjects, particularly in monocyte-derived alveolar macrophages.
217 Notably, although IFN response genes were reduced in Ob subjects in peripheral blood, this
218 phenomenon was much less marked outside of tissues and there was a disconnect between BAL
219 and blood in terms of TNF response genes, suggesting attenuated tissue responses, but a more

220 exuberant, potentially pathogenic systemic pro-inflammatory landscape, and emphasising the
221 importance of studies assessing tissue immunity, despite the practical challenges associated.

222

223 Overall, our study has important translational implications; current and proposed treatments for
224 severe COVID-19 include anti-inflammatory agents such as IL6R blocking antibodies and the
225 application of recombinant IFN α and IFN β to promote early anti-viral responses, with the latter
226 showing limited efficacy in an early trial²⁹. However, this study was small and included only patients
227 with mild disease, and there is an increasing recognition for the need to tailor the different
228 treatment strategies available to the correct patient group, at the correct time¹⁶. Our data show a
229 markedly muted response to type I IFN and IFN γ in tissue immune cells in the respiratory tract in
230 Ob COVID-19 patients across lifespan, as well as reduced transcripts of these cytokines,
231 supporting the application of locally-delivered, inhaled recombinant type I IFNs to respiratory tract
232 tissues in this vulnerable subset.

233

234

235

236 **Acknowledgements:**

237 GB is funded by a Wellcome Strategic Scientific award (WT211276/Z/18/Z). ZKT and MRC are
238 supported by a Medical Research Council Research Project Grant (MR/S035842/1). JRF and
239 MRC are supported by the National Institute of Health Research (NIHR) Blood and Transplant
240 Research Unit in Organ Donation, and NR, MM, GD and MRC by the NIHR Cambridge Biomedical
241 Research Centre. MZN acknowledges funding from the Rutherford Fund Fellowship allocated by
242 the Medical Research Council and the UK Regenerative Medicine Platforms 2 (MR/5005579/1).
243 KBM acknowledges funding from Wellcome (WT211276/Z/18/Z and Sanger core grant
244 WT206194), the Chan Zuckerberg Foundation (grants 2017-174169 and 2019-202654) and the
245 European Union's Horizon 2020 research and innovation programme under grant agreement No
246 874656. The views expressed are those of the author(s) and not necessarily those of the NHS,
247 the NIHR or the Department of Health and Social Care. The CL3 for this research was partly
248 funded by the NIHR AMR Research Capital Funding Scheme [NIHR200640]. We are grateful to
249 the Evelyn Trust (20/75), Addenbrooke's Charitable Trust, Cambridge University Hospitals
250 (12/20A), the NIHR Cambridge Biomedical Research Centre, Rosetrees Trust (M944), Action
251 Medical Research (GN2911) and the UKRI/NIHR through the UK Coronavirus Immunology
252 Consortium (UK-CIC) for their financial support. RGW and AVM are funded by NIH NIAID
253 U19AI35964. ACM is supported by a Clinician Scientist Fellowship from the Medical Research
254 Council (MR/V006118/1). MRC and SAG by an NIHR Research Professorship RP-2017-08-ST2-
255 002).

256

257

258 **References**

- 259 1. Guan, W.J., *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N. Engl.*
260 *J. Med.* (2020).
- 261 2. Williamson, E.J., *et al.* Factors associated with COVID-19-related death using
262 OpenSAFELY. *Nature* **584**, 430-436 (2020).
- 263 3. Tartof, S.Y., *et al.* Obesity and Mortality Among Patients Diagnosed With COVID-19:
264 Results From an Integrated Health Care Organization. *Ann. Intern. Med.* **173**, 773-781
265 (2020).
- 266 4. Anderson, M.R., *et al.* Body Mass Index and Risk for Intubation or Death in SARS-CoV-2
267 Infection : A Retrospective Cohort Study. *Ann. Intern. Med.* **173**, 782-790 (2020).
- 268 5. Collier, D.A., *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
269 *Nature* **593**, 136-141 (2021).
- 270 6. Hales, C.M., Carroll, M.D., Fryar, C.D. & Ogden, C.L. Prevalence of Obesity and Severe
271 Obesity Among Adults: United States, 2017-2018. *NCHS Data Brief*, 1-8 (2020).
- 272 7. Dixon, A.E. & Peters, U. The effect of obesity on lung function. *Expert Rev. Respir. Med.*
273 **12**, 755-767 (2018).
- 274 8. Kern, P.A., Ranganathan, S., Li, C., Wood, L. & Ranganathan, G. Adipose tissue tumor
275 necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am.*
276 *J. Physiol. Endocrinol. Metab.* **280**, E745-751 (2001).
- 277 9. Strackowski, M., *et al.* Plasma interleukin-8 concentrations are increased in obese
278 subjects and related to fat mass and tumor necrosis factor-alpha system. *J. Clin.*
279 *Endocrinol. Metab.* **87**, 4602-4606 (2002).
- 280 10. Kanda, H., *et al.* MCP-1 contributes to macrophage infiltration into adipose tissue, insulin
281 resistance, and hepatic steatosis in obesity. *J. Clin. Invest.* **116**, 1494-1505 (2006).
- 282 11. Lord, G.M., *et al.* Leptin modulates the T-cell immune response and reverses starvation-
283 induced immunosuppression. *Nature* **394**, 897-901 (1998).
- 284 12. Naylor, C. & Petri, W.A., Jr. Leptin Regulation of Immune Responses. *Trends Mol. Med.*
285 **22**, 88-98 (2016).
- 286 13. Smith, A.G., Sheridan, P.A., Harp, J.B. & Beck, M.A. Diet-induced obese mice have
287 increased mortality and altered immune responses when infected with influenza virus. *J.*
288 *Nutr.* **137**, 1236-1243 (2007).
- 289 14. van der Voort, P.H.J., *et al.* Leptin levels in SARS-CoV-2 infection related respiratory
290 failure: A cross-sectional study and a pathophysiological framework on the role of fat
291 tissue. *Heliyon* **6**, e04696 (2020).
- 292 15. Wang, J., *et al.* Leptin correlates with monocytes activation and severe condition in COVID-
293 19 patients. *J. Leukoc. Biol.* **110**, 9-20 (2021).
- 294 16. Kim, Y.M. & Shin, E.C. Type I and III interferon responses in SARS-CoV-2 infection. *Exp.*
295 *Mol. Med.* **53**, 750-760 (2021).
- 296 17. Andrade, F.B., *et al.* The Weight of Obesity in Immunity from Influenza to COVID-19. *Front*
297 *Cell Infect Microbiol* **11**, 638852 (2021).
- 298 18. Liao, M., *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with
299 COVID-19. *Nat. Med.* **26**, 842-844 (2020).
- 300 19. Grant, R.A., *et al.* Circuits between infected macrophages and T cells in SARS-CoV-2
301 pneumonia. *Nature* **590**, 635-641 (2021).
- 302 20. Nicklin, M.J., Hughes, D.E., Barton, J.L., Ure, J.M. & Duff, G.W. Arterial inflammation in
303 mice lacking the interleukin 1 receptor antagonist gene. *J. Exp. Med.* **191**, 303-312 (2000).
- 304 21. Johnen, H., *et al.* Tumor-induced anorexia and weight loss are mediated by the TGF-beta
305 superfamily cytokine MIC-1. *Nat. Med.* **13**, 1333-1340 (2007).

- 306 22. Yoshida, M., *et al.* Local and systemic responses to SARS-CoV-2 infection in children and
307 adults. *Nature* (2021).
- 308 23. Littwitz-Salomon, E., Malyskina, A., Schimmer, S. & Dittmer, U. The Cytotoxic Activity of
309 Natural Killer Cells Is Suppressed by IL-10(+) Regulatory T Cells During Acute Retroviral
310 Infection. *Front. Immunol.* **9**, 1947 (2018).
- 311 24. Perlin, D.S., *et al.* Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized
312 COVID-19 Patients with Cytokine Release Syndrome and ARDS. *mSphere* **5**(2020).
- 313 25. Stephenson, E., *et al.* Single-cell multi-omics analysis of the immune response in COVID-
314 19. *Nat Med* (2021).
- 315 26. Easterbrook, J.D., *et al.* Obese mice have increased morbidity and mortality compared to
316 non-obese mice during infection with the 2009 pandemic H1N1 influenza virus. *Influenza*
317 *Other Respir Viruses* **5**, 418-425 (2011).
- 318 27. Smith, A.G., Sheridan, P.A., Tseng, R.J., Sheridan, J.F. & Beck, M.A. Selective impairment
319 in dendritic cell function and altered antigen-specific CD8+ T-cell responses in diet-induced
320 obese mice infected with influenza virus. *Immunology* **126**, 268-279 (2009).
- 321 28. Karlsson, E.A., Sheridan, P.A. & Beck, M.A. Diet-induced obesity impairs the T cell
322 memory response to influenza virus infection. *J. Immunol.* **184**, 3127-3133 (2010).
- 323 29. Monk, P.D., *et al.* Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for
324 treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled,
325 phase 2 trial. *Lancet Respir Med* **9**, 196-206 (2021).
- 326 30. Morse, C., *et al.* Proliferating SPP1/MERTK-expressing macrophages in idiopathic
327 pulmonary fibrosis. *Eur. Respir. J.* **54**(2019).
- 328 31. Hao, Y., *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-
329 3587.e3529 (2021).
- 330 32. Young, M.D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based
331 single-cell RNA sequencing data. *Gigascience* **9**(2020).
- 332 33. McGinnis, C.S., Murrow, L.M. & Gartner, Z.J. DoubletFinder: Doublet Detection in Single-
333 Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* **8**, 329-337.e324
334 (2019).
- 335 34. Korsunsky, I., *et al.* Fast, sensitive and accurate integration of single-cell data with
336 Harmony. *Nat Methods* **16**, 1289-1296 (2019).
- 337 35. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection
338 for Dimension Reduction. *J Open Source Softw* **3**, 861 (2018).
- 339 36. Wu, T., *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.
340 *Innovation (N Y)* **2**, 100141 (2021).
- 341 37. Efremova, M., Vento-Tormo, M., Teichmann, S.A. & Vento-Tormo, R. CellPhoneDB:
342 inferring cell-cell communication from combined expression of multi-subunit ligand-
343 receptor complexes. *Nat. Protoc.* **15**, 1484-1506 (2020).
- 344
345

346 **Figure legends**

347

348 **Figure 1. Single-cell analysis of bronchoalveolar lavage (BAL) fluid samples from patients**
349 **with or without COVID-19 reveals differences in geneset enrichment in structural and**
350 **myeloid cells in non-obese compared with obese subjects.**

351 a. Overview of the workflow. In this study, we included BAL samples from 33 patients from three
352 cohorts with BMI information, namely UCAM (n=8; ob=3; this study), SZH (n=13; ob=1; Liao et al.,
353 2020), and NU (n=12; ob=9; Grant et al., 2021).

354 b. UMAP embedding of 189,312 cells post-integration of the 3 datasets. Cells are coloured
355 according to harmonised broad cell type annotations.

356 c. UMAP embedding of 4,989 epithelial and structural cells post-integration coloured according to
357 harmonised fine cell type annotations.

358 d. Dot plot of gene set enrichment analysis of top 5 most enriched immune pathways within
359 Hallmark gene sets for epithelial/structural cells. Mean expression of genes contained in each
360 gene set within each cell type (labelled A-I; see c.), separated into non-obese vs. obese groups,
361 are indicated by colour gradients. P values are indicated by dot sizes.

362 e. UMAP embedding of 122,928 myeloid cells coloured according to fine cell type annotation as
363 per Grant et al. (2021). MoAM indicates monocyte-derived macrophage, TRAM indicates tissue-
364 resident macrophage

365 f. Dot plot of gene set enrichment analysis of top 5 most enriched immune pathways within
366 Hallmark gene sets for myeloid cells. Mean expression of genes contained in each gene set within
367 each cell type (labelled A-F; see e.), separated into non-obese vs. obese groups, are indicated by
368 colour gradients. P values are indicated by dot sizes.

369 g. Violin plot depicting mean expression levels of transcripts for cytokines and chemokines in each
370 macrophage subpopulation. Differences between Non-obese vs. Obese with or without COVID-
371 19 infection remain significant by Wilcoxon rank sum test.

372 h. Dot plot of gene set enrichment analysis of Hallmark gene sets in myeloid cells from paediatric
373 airway samples (Yoshida et al. (2021)) between non-obese vs. obese children. Normalized
374 enrichment score (NES) of each pathway is indicated by dot size. Colour of circles indicate which
375 comparison was significantly enriched (healthy or COVID-19); grey circles are not significant.

376

377 **Figure 2. Single-cell analysis of lymphocytes shows reduced enrichment of type I and**
378 **gamma interferon response genes in obese COVID-19 patients.**

379 a. UMAP embedding of 34,703 T/NK cells post-integration. CD4 T cells (Tcm: central memory T
380 cells; Tem: effector memory T cells; Tnaive: naive T cells; and Treg), CD8 T cells (Tem, Tnaive,
381 and MAIT), NKT cells, and NK cells (CD56-high or CD56-low).

382 b. Dot plot of gene set enrichment analysis of top 5 most enriched immune pathways within
383 Hallmark gene sets for T/NK cells. Mean expression of genes contained in each gene set within

384 each cell type (labelled A-J; see a.), separated into non-obese vs obese groups, are indicated by
385 colour gradients. P values are indicated by dot sizes.

386 c. Dot plot of gene set enrichment analysis of Hallmark gene sets in T/NK/ILC cells from paediatric
387 airway samples (Yoshida et al. (2021)) between non-obese vs. obese children. Normalized
388 enrichment score (NES) of each pathway is indicated by dot size. Colour of circles indicate which
389 comparison was significantly enriched (healthy or COVID-19); grey circles are not significant.

390 d. Ligand-receptor analysis with CellPhoneDB infers distinct interactions between CD8.Tem /
391 CD8.Tnaive / NK.CD56hi and alveolar macrophages. Size and colour gradient of circles indicate
392 the scaled interaction score; interaction scores are scaled row-wise. Red outline indicates a P
393 value < 0.05.

394 e. UMAP embedding of 8,857 B/plasma cells post-integration coloured according to harmonised
395 fine cell type annotations.

396 f. Dot plot of gene set enrichment analysis of top 5 most enriched immune pathways within
397 Hallmark gene sets for B/plasma cells. Mean expression of genes contained in each gene set
398 within each cell type (labelled A-J; see e.), separated into non-obese vs. obese groups, are
399 indicated by colour gradients. P values are indicated by dot sizes.

400 g. Mean expression dot plots of transcripts for IFN- α / β / γ , IFN receptors, IL6, and TNF- α in myeloid
401 cells in the BAL samples. Expression levels in each case are indicated by distinct colour gradients
402 (Green: Non-obese without COVID-19; Yellow: Non-obese with COVID-19; Purple: Obese without
403 COVID-19; Magenta: Obese with COVID-19). Expression percentages are indicated by dot sizes.

404 h. Serum IFN- α measurements from n=4 obese and n=4 Non-obese patients from the adult PBMC
405 patient cohort (Stephenson et al.). All 4 Obese samples were below detection limits.

406

407

408 **Figure S1 – Patient sampling and cellular composition of BAL**

409 a. Distribution of patient's days from ICU admission to BAL sampling between obese (BMI>30)
410 and non-obese (BMI<30) groups. Wilcoxon rank sum test where $p < 0.05$ was considered
411 statistically significant.

412 b. Mean expression dot plot of transcripts for canonical marker genes in each major population in
413 the BAL samples. Expression levels are indicated by colour gradients. Expression percentages
414 are indicated by dot sizes.

415 c. Proportions of each major population in each cohort grouped by infection (COVID+/-) and
416 obesity (Non-Obese/Obese) states. Each bar indicates the cell type proportions in an individual
417 sample.

418 d. Proportions of each major population in each cohort contributed by each sample (indicated by
419 colour codes) (Black: NU; Gray: SZH; Light Gray: UCAM). Each bar indicates a cell type.

420

421 **Figure S2 - Structural cells and myeloid cells in the BAL samples**

- 422 a. Mean expression dot plot of transcripts for canonical marker genes in each epithelial
423 subpopulation in the BAL samples. Expression levels are indicated by colour gradients.
424 Expression percentages are indicated by dot sizes.
- 425 b. Mean expression dot plot of the top differentially expressed cytokines and chemokines in each
426 epithelial subpopulation in the COVID+ BAL samples. Expression levels in each case are indicated
427 by distinct colour gradients (Blue: Non-obese; Magenta: Obese). Expression percentages are
428 indicated by dot sizes.
- 429 c. Flow cytometry quantification of alveolar macrophages (SSC^{hi}CD206⁺, left) and neutrophils
430 (SSC^{hi}CD206⁻CD24⁺CD16⁺, right) as a proportion of live CD45⁺ cells in the BAL fluid of obese and
431 non-obese SARS-CoV-2 positive/negative patients (n=6 patients from the Cambridge study only).
- 432 d. Mean expression dot plot of transcripts for canonical marker genes in each macrophage
433 subpopulation in the BAL samples. Expression levels are indicated by colour gradients.
434 Expression percentages are indicated by dot sizes. MoAM: Monocyte-derived alveolar
435 macrophage; TRAM: Tissue-resident alveolar macrophage.
- 436 e. Dot plot of gene set enrichment analysis of most enriched immune pathways within Hallmark
437 gene sets for each macrophage subpopulation. Mean expression of genes contained in each gene
438 set within each cell type, separated into non-obese vs. obese and COVID- vs. COVID+ groups,
439 are indicated by colour gradients. P values are indicated by dot sizes.
- 440 f. Dot plot of gene set enrichment analysis of most enriched immune pathways within Hallmark
441 gene sets for classical dendritic cells (cDC) and plasmacytoid dendritic cells (pDC). Mean
442 expression of genes contained in each gene set within each cell type, separated into non-obese
443 vs. obese and COVID- vs. COVID+ groups, are indicated by colour gradients. P values are
444 indicated by dot sizes.
- 445 g. Scatter plot of mean expression levels (y-axis) of the leading-edge genes in the signaling
446 pathways IFN α Response, IFN γ Response, and TNF α Signaling via NF- κ B versus days from ICU
447 admission to BAL sampling (x-axis) across macrophage subpopulations. MoAM, monocyte-
448 derived alveolar macrophage; TRAM, tissue-resident alveolar macrophage.
- 449 h. Mean expression dot plot of the top differentially expressed cytokines and chemokines in each
450 macrophage subpopulation in the COVID+ BAL samples. Expression levels in each case are
451 indicated by distinct colour gradients (Blue: Non-obese; Magenta: Obese). Expression
452 percentages are indicated by dot sizes.
- 453 i. Mean expression dot plots of transcripts for the top differentially expressed cytokines and
454 chemokines in each dendritic cell subpopulation in the BAL samples. Expression levels in each
455 case are indicated by distinct colour gradients (Green: Non-obese without COVID-19; Yellow:
456 Non-obese with COVID-19; Purple: Obese without COVID-19; Magenta: Obese with COVID-19).
457 Expression percentages are indicated by dot sizes.

458

459 **Figure S3 - T cells and NK cells in the BAL samples**

- 460 a. Mean expression dot plot of transcripts for canonical marker genes in each T/NK subpopulation
461 in the BAL samples. Expression levels are indicated by colour gradients. Expression percentages
462 are indicated by dot sizes. Tcm: central memory T cells; Tem: effector memory T cells; Tnaive:
463 naive T cells; Treg: regulatory T cells; MAIT: mucosal associated invariant T cells.
- 464 b. Dot plot of gene set enrichment analysis of most enriched immune pathways within Hallmark
465 gene sets for each T/NK subpopulation. Mean expression of genes contained in each gene set
466 within each cell type, separated into non-obese vs. obese and COVID- vs. COVID+ groups, are
467 indicated by colour gradients. P values are indicated by dot sizes.
- 468 c. Scatter plot of mean expression levels (y-axis) of the leading-edge genes in the signaling
469 pathways IFN α Response, IFN γ Response, and TNF α Signaling via NF- κ B versus days from ICU
470 admission to BAL sampling (x-axis) across T or NK subpopulations.
- 471 d. Mean expression dot plot of the top differentially expressed cytokines and chemokines in each
472 T/NK subpopulation in the COVID+ BAL samples. Expression levels in each case are indicated
473 by distinct colour gradients (Blue: Non-obese; Magenta: Obese). Expression percentages are
474 indicated by dot sizes.

475

476 **Figure S4 - B cells and plasma cells in the BAL samples**

- 477 a. Mean expression dot plot of transcripts for canonical marker genes in each B/Plasma
478 subpopulation in the BAL samples. Expression levels are indicated by colour gradients.
479 Expression percentages are indicated by dot sizes.
- 480 b. Heatmap of Pearson's correlation analysis between our annotated cell types and the public data
481 from Monaco et al. 2019
- 482 c. Dot plot of gene set enrichment analysis of most enriched immune pathways within Hallmark
483 gene sets for each B/Plasma subpopulation. Mean expression of genes contained in each gene
484 set within each cell type, separated into non-obese vs. obese and COVID- vs. COVID+ groups,
485 are indicated by colour gradients. P values are indicated by dot sizes.
- 486 d. Scatter plot of mean expression levels (y-axis) of the leading-edge genes in the signaling
487 pathways IFN α Response, IFN γ Response, and TNF α Signaling via NF- κ B versus days from ICU
488 admission to BAL sampling (x-axis) across B subpopulations and plasma cells.
- 489 e. Dot pot of gene set enrichment analysis of Hallmark gene sets in B/Plasma cells from paediatric
490 airway samples (Yoshida et al. (2021)) between non-obese vs. obese children. Normalized
491 enrichment score (NES) of each pathway is indicated by dot size. Colour of circles indicate which
492 comparison was significantly enriched (healthy or COVID-19); grey circles are not significant.

493

494 **Figure S5 – Validation of the signaling pathways in PBMC samples**

- 495 a. Sample demographics of Stephenson et al. 2021²² PBMC samples used in this study.
- 496 b. Dot plot of gene set enrichment analysis of most enriched immune pathways within Hallmark
497 gene sets for each T/NK/ILC subpopulation in PBMCs. Mean expression of genes contained in

498 each gene set within each cell type, separated into non-obese vs. obese groups, are indicated by
499 colour gradients. P values are indicated by dot sizes.

500 d. Dot plot of gene set enrichment analysis of most enriched immune pathways within Hallmark
501 gene sets for each B/Plasma subpopulation in PBMCs. Mean expression of genes contained in
502 each gene set within each cell type, separated into non-obese vs. obese groups, are indicated by
503 colour gradients. P values are indicated by dot sizes.

504

505 **Figure S6 – Expression patterns of the selected cytokines and their receptors in the BAL**
506 **samples.**

507 a. Mean expression dot plots of transcripts for the selected cytokines and their receptors in each
508 major population in the BAL samples. Expression levels in each case are indicated by distinct
509 colour gradients (Green: Non-obese without COVID-19; Yellow: Non-obese with COVID-19;
510 Purple: Obese without COVID-19; Magenta: Obese with COVID-19). Expression percentages are
511 indicated by dot sizes.

512 b. Mean expression dot plots of transcripts for the selected cytokines in each T/NK subpopulation
513 in the BAL samples. Expression levels in each case are indicated by distinct colour gradients
514 (Green: Non-obese without COVID-19; Yellow: Non-obese with COVID-19; Purple: Obese without
515 COVID-19; Magenta: Obese with COVID-19). Expression percentages are indicated by dot sizes.

516

517 **Figure S7 – Expression patterns of the selected cytokines and their receptors in PBMCs**

518 a. Mean expression dot plots for IFNA1, IFNA2, IFNB and IFNG in PBMC cell clusters from
519 Stephenson et al. 2021²² grouped according to BMI status. Size of circles correspond to fraction
520 of cells expressing each gene and increasing gradient from purple to yellow corresponds to
521 increasing mean expression value (standardized to 0 to 1 per gene).

522 b. Mean expression dot plots for IFNAR1, IFNAR2, IFNGR1 and IFNGR2 in PBMC cell clusters
523 from²² grouped according to BMI status. Size of circles correspond to fraction of cells expressing
524 each gene and increasing gradient from purple to yellow corresponds to increasing mean
525 expression value (standardized to 0 to 1 per gene).

526

527 **Figure S8 – Expression patterns of the selected cytokines and their receptors in PBMCs**

528 a. Mean expression dot plots for TNF and IL6 in PBMC cell clusters from Stephenson et al. 2021
529 ²² grouped according to BMI status. Size of circles correspond to fraction of cells expressing each
530 gene and increasing gradient from purple to yellow corresponds to increasing mean expression
531 value (standardized to 0 to 1 per gene).

532 b. Mean expression dot plots for TNFRSF1A, TNFRSF1B and IL6R in PBMC cell clusters from²²
533 grouped according to BMI status. Size of circles correspond to fraction of cells expressing each
534 gene and increasing gradient from purple to yellow corresponds to increasing mean expression
535 value (standardized to 0 to 1 per gene).

536 **Methods**

537

538 **Patient recruitment and consent**

539 The BAL samples from UCAM were collected in the Addenbrookes Hospital Intensive Care Unit
540 under our discard lavage protocol. The use of discard samples surplus to that required for clinical
541 testing, and anonymised data review were conducted under the consent waiver granted by Leeds
542 West NHS Research Ethics Committee (ref: 20/YH/0152). Inclusion criteria were ‘adult (age >16)
543 patients admitted to ICU for mechanical ventilation undergoing bronchoalveolar lavage for the
544 investigation of suspected pneumonia’. Exclusion criteria were non-ventilated patients, age <16
545 years, and patients with restricted access to notes. For blood samples, ethical approval was
546 obtained from the East of England – Cambridge Central Research Ethics Committee (“NIHR
547 BioResource” REC ref 17/EE/0025, and “Genetic variation AND Altered Leukocyte Function in
548 health and disease - GANDALF” REC ref 08/H0308/176). All participants provided informed
549 consent. For paediatric nasal brushings, BMI data was obtained (where possible) on patients
550 included in the UK Cohort of Yoshida *et al.* 2021²². Details of consent and methodology are found
551 here.

552

553 **Isolation of the cells from BALF**

554 Samples of 5-20ml BAL were collected and processed under BSL3 conditions. If necessary, the
555 samples were filtered prior to processing by passing through a 100µm cell strainer to remove large
556 mucus aggregates. Samples were subsequently topped up with PBS to 50ml and centrifuged at
557 400xg for 5 min. The supernatant was removed, and the cells were resuspended in 100µl of PBS.
558 20µl of Human fc block was added (Milteni) followed by 10µl of a custom TotalSeq -C Human
559 cocktail. Cells were stained for 30min, topped up with PBS and washed as before.

560

561 **Single-cell encapsulation, library preparation, and sequencing**

562 Cells were resuspended in 50µl, counted, and loaded on Chromium Chip A (10x Genomics, 5’v3)
563 for cell encapsulation. cDNA libraries were prepared per manufacturer’s recommendation. After
564 quality checks with Bioanalyzer (Agilent; 2100), the libraries were pooled and sequenced with
565 NovaSeq 6000.

566

567 **Isolation of PBMCs and granulocytes.**

568 PBMC and granulocytes were isolated by discontinuous density gradient centrifugation in 60%
569 and 80% Percoll at 800g for 15 minutes. PBMC and granulocyte layers were taken off and washed
570 separately in PBS at 300xg for 10 minutes. Cells were counted and 1-3x10⁶ cells from each of the
571 PBMC and granulocyte layers were separately stained for flow cytometry.

572

573 **Flow cytometry.**

574 After aliquots were taken for single-cell RNA sequencing, remaining BAL fluid cells, PBMC and
575 granulocytes were blocked with human FcR block (Miltenyi Biotech, Bisley, UK) and incubated
576 with antibodies (see table) for 30 minutes at 4°C, then washed in PBS and resuspended in FACS
577 fix. Samples were processed on a Fortessa flow cytometer (Becton Dickinson, Basel, Switzerland)
578 and data analysed using Flowjo version 10.

579

580

Table 1. List of antibodies used in flow cytometry

Marker	Fluorophore	Clone	Company	Cat. No.
CD4	FITC	RPA-T4	Thermo Fisher Scientific	11-0049-42
CD24	PerCPy5.5	ML5	Biolegend	311106
CD64	APC	10.1	Thermo Fisher Scientific	17-0649-42
CD3	AF700	UCHT1	Biolegend	300424
CD19	APC-Cy7	SJ25-C1	Thermo Fisher Scientific	A15429
CD14	Pacific blue	61D3	Thermo Fisher Scientific	48-0149-42
Live/Dead	Aqua	NA	Thermo Fisher Scientific	L34957
CD11c	BV605	3.9	Biolegend	301636
CD45	BV650	HI30	Biolegend	304044
CD56	BV785	5.1H11	Biolegend	362550
CD206	PE	19.2	Thermo Fisher Scientific	12-2069-42
CD16	PE-Cy7	eBioCB16	Thermo Fisher Scientific	25-0168-42

581

582 **Public datasets.**

583 We have included two public single-cell RNA-seq datasets from Liao et al. (2020)¹⁸ and Grant et
584 al. (2021)¹⁹ for multi-sample integration. The data were acquired from Gene Expression Omnibus
585 (GEO) database under accession codes GSE145926 and GSE155249, respectively. The
586 additional healthy control BAL sample (Morse et al., 2019; GSE128033)³⁰ analyzed in Liao et al.
587 (2020)¹⁸ has also been included.

588

589 **Single-cell RNA-seq data alignment and multi-sample integration.**

590 Data were processed using the Cell Ranger 3.1.0 pipeline (10x Genomics). The generated count
591 tables with UMI counts > 1000, gene number > 200, and mitochondrial genes < 10% were
592 analysed using the Seurat³¹ software package (4.0.4) in R (4.0), ambient RNA was corrected with
593 SoupX³² (1.5.2), doublets were detected with DoubletFinder³³ (2.0.3) and removed, and multi-
594 sample integration was performed with harmony³⁴ (1.0) to remove batch effects across different
595 patients. In parameter settings, the first 50 dimensions of principal-component analysis (PCA)
596 were used, and the cells were clustered using the FindClusters function with a resolution of 0.5.
597 Uniform Manifold Approximation and Projection (UMAP)³⁵ v(0.5.2) was used for visualizing the
598 data.

599

600 **Differential gene expression analysis**

601 Wilcox test in FindAllMarkers or FindMarkers function in Seurat was used to compare the
602 differential gene expression across major or minor cell types or within each subpopulation of
603 structural cells, macrophages, T/NK cells, B/Plasma cells, or dendritic cells between non-obese
604 and obese cases, respectively.

605

606 **Re-integration of structural cells, macrophages, T / NK cells, and B cells.**

607 Major cell types including structural cells, macrophages, T / NK cells, and B cells were re-clustered
608 with Seurat (4.0.4), followed by removal of batch effect across different patients with harmony
609 (1.0). Cells were clustered using the FindClusters function with resolutions between 0.4-1.0
610 (structural cells: 0.5; myeloid cells: 0.4; T cells: 1.0; B cells: 1.0).

611

612 **Gene set enrichment analysis (GSEA)**

613 clusterProfiler³⁶ (3.18.1) was used to perform GSEA. Briefly, genes from each of the
614 subpopulations were ranked in a descending order of their expression levels between non-obese
615 and obese cases by using FindMarker function. Those with log fold changes > 0.5 or < -0.5 were
616 selected for GSEA using compareCluster function. Hallmark gene sets in msigdb (7.4.1) and
617 enricher function in clusterProfiler were used for gene functional annotation.

618

619 **Calculation of the cytokine module score**

620 The module score was calculated using AddModuleScore function in Seurat with the cytokine and
621 chemokine gene set from KEGG pathway.

622

623 **Ligand-receptor analysis**

624 Ligand-receptor analysis was performed with CellPhoneDB³⁷ and was visualized with ktplots using
625 plot_cpdb function. Briefly, the normalized counts and meta data extracted from Seurat objects
626 were applied for the statistical analysis from CellPhoneDB in python 3.8.8. The resulting p values
627 and means were then filtered and visualized with ktplots.

628

629 **Visualization**

630 Plotting was performed using ggplot2 (3.3.5). Heatmap was generated using pheatmap (1.0.12).
631 Figure layouts were edited in Affinity Designer (1.10.0).

632

633 **Statistics**

634 Statistical analysis was performed using base R (4.0) with tidyverse (1.3.0). Wilcoxon tests were
635 performed in FigS1a using stat_compare_means function in ggpubr with 'wilcox.test' indicated in
636 method parameter

Figure 1.







Figure 2.




S1



S2




S3




S4


a Expression Levels of Canonical Markers




b




c



e




d




S5


a



b




c




S6

a




b




S7

a




b



S8

a



b

